Long-acting antiretroviral therapy in low-income and middle-income countries: considerations for roll-out
Open Access
- 11 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 20 (1) , 19-24
Abstract
Purpose of review: Long-acting ART (LA-ART) in low-income and middle-income countries (LMICs) may address specific issues that affect people living with HIV (PWH) and people at substantial risk of HIV infection. We reviewed products in use and under consideration in LMICS, current and anticipated challenges for implementation, and offer strategies for effective rollout. Recent findings: Factors to consider for effective implementation of LA-ART in LMICs are: managing co-conditions (pregnancy) and comorbidities (TB and hepatitis B); medication access, both cost and supply-related; and health systems delivery mechanisms for products. Summary: LA-ART present promising new alternatives in LMICs. Although they may tackle certain adherence concerns and systemic issues, which impact delivery of services, significant obstacles remain before their widespread implementation in people that require them most, particularly in countries most affected by HIV. We offer best practices from prior experiences and implementation studies for effective coordination of multiple stakeholders, critical for effective rollout.Keywords
This publication has 44 references indexed in Scilit:
- Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines PanelJAMA, 2024
- What will it take for an injectable ARV to change the face of the HIV epidemic in high‐prevalence countries? Considerations regarding drug costs and operationsJournal of the International AIDS Society, 2023
- Preparing for long‐acting PrEP delivery: building on lessons from oral PrEPJournal of the International AIDS Society, 2023
- Securing accelerated access to long‐acting injectable cabotegravir for HIV prevention in low‐ and middle‐income countriesJournal of the International AIDS Society, 2023
- Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infectionAdvanced Drug Delivery Reviews, 2023
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in AdultsJAMA, 2023
- HIV prevention: better choice for better coverageJournal of the International AIDS Society, 2022
- Exploring Perceived Barriers and Facilitators of PrEP Uptake among Young People in Uganda, Zimbabwe, and South AfricaArchives of Sexual Behavior, 2021
- Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077AIDS and Behavior, 2020
- Cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of HIV testing programmes in low‐income settings in southern Africa: health economic and modelling analysisJournal of the International AIDS Society, 2019